Symposium
The First International Symposium on ctDNA-RECIST
The symposium aims to bring together clinicians and researchers dedicated to the field of circulating tumor DNA, emphasizing both the exploration of ctDNA in research and its clinical application as a tool for evaluating treatment response. By spotlighting this critical area of study at an early stage, the event seeks to foster international collaboration, accelerate research progress, and build a strong foundation for future advancements in the field.
A key objective of the symposium will be the strategic planning and coordination of international clinical trials, ensuring that efforts are aligned to maximize the impact and clinical utility of ctDNA measurements as treatment response criteria.
When?
14-15 March 2025
Where?
Aarhus, Denmark
Helnan Marselis Hotel
Registration
Registration deadline is 7 February 2025
Who?
Anyone interested in ctDNA-RECIST (this symposium is not for the industry).
Organizing Committee
Karen-Lise Garm Spindler, Aarhus, Denmark
Klaus Pantel, Hamburg, Germany
Aziz Zaanan, Paris, France
Remond Fijneman, Amsterdam, The Netherlands
Dirk Arnold, Hamburg, Germany
Malene Støchkel Frank, Roskilde, Denmark
Practical information
You can find practical information and register for the symposium here
Curious to learn more?
Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer
Karen-Lise Garm Spindler, Anders Jacobsen
(2023, April). Therapeutic Advances in Medical Oncology, vol 15. Pages 1-11. Doi: 10.1177/17588359231171580
ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology
Anders K. M. Jakobsen, Karen-Lise Garm Spindler
(2023, February). European Journal of Cancer, 180. Pages 180-183. doi: 10.1016/j.ejca.2022.11.039. PMID: 36610263
About the symposium
In the context of metastatic cancers, decisions regarding systemic palliative therapies often rely on the Response Evaluation Criteria in Solid Tumors (RECIST), a method primarily utilizing imaging. With Karen-Lise Garm Spindler in front, a network proposes a ctDNA-RECIST instead, a response classification based on circulating tumor DNA measurements and its confidence intervals. They aim to raise the topic for discussion.
The symposium aims at bringing together clinicians and researchers involved in ctDNA research and clinical utilization of ctDNA measurements as treatment response criteria.
It will bring focus to the topic at an early stage and strengthen international collaboration, research development and planning of international clinical trials.
The program will include disussions on:
ctDNA analysis
clinical trials
clinical implementation
change of culture among oncologists
The symposium aims to strengthen the international collaboration in working on the ctDNA-RECIST criteria.
ADDRESS FOR THE SECRETARIAT
Science Center Skejby, MOMA
Brendstrupgårdsvej 21, build. A
8200 Aarhus N
CONTACT
ctDNA@clin.au.dk
+45 78 45 53 39